BRPI0719166A2 - Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos - Google Patents

Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos

Info

Publication number: BRPI0719166A2
Authority: BR; Brazil
Prior art keywords: therapeutic agents; tricyclic spiro; oxindol derivatives; oxindol; derivatives
Prior art date: 2006-10-12

Application number

BRPI0719166-9A2A

Other languages

English (en)

Inventor

Mikhail Chafeev

Sultan Chowdhury

Jianmin Fu

Rajender Kamboj

Original Assignee

Xenon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-12

Filing date

2007-10-12

Publication date

2014-06-03

2007-10-12 Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc

2014-06-03 Publication of BRPI0719166A2 publication Critical patent/BRPI0719166A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0719166-9A2A 2006-10-12 2007-10-12 Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos BRPI0719166A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US85119006P	2006-10-12	2006-10-12
PCT/US2007/081240 WO2008046046A1 (en)	2006-10-12	2007-10-12	Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents

Publications (1)

Publication Number	Publication Date
BRPI0719166A2 true BRPI0719166A2 (pt)	2014-06-03

Family

ID=39046816

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0719166-9A2A BRPI0719166A2 (pt)	2006-10-12	2007-10-12	Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos

Country Status (9)

Country	Link
US (1)	US20110237567A9 (pt)
EP (1)	EP2076518A1 (pt)
JP (1)	JP2010522690A (pt)
CN (1)	CN101522685A (pt)
AU (1)	AU2007307635A1 (pt)
BR (1)	BRPI0719166A2 (pt)
CA (1)	CA2666136A1 (pt)
MX (1)	MX2009003874A (pt)
WO (1)	WO2008046046A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR053710A1 (es) *	2005-04-11	2007-05-16	Xenon Pharmaceuticals Inc	Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY144968A (en)	2005-04-11	2011-11-30	Xenon Pharmaceuticals Inc	Spiro-oxindole compounds and their uses as therapeutic agents
CL2007002953A1 (es) *	2006-10-12	2008-02-01	Xenon Pharmaceuticals Inc	Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
AR063280A1 (es)	2006-10-12	2009-01-21	Xenon Pharmaceuticals Inc	Uso de compuestos de espiro-oxindol como agentes terapeuticos
CA2741024A1 (en) *	2008-10-17	2010-04-22	Xenon Pharmaceuticals Inc.	Spiro-oxindole compounds and their use as therapeutic agents
CA2741029A1 (en)	2008-10-17	2010-04-22	Xenon Pharmaceuticals Inc.	Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es)	2009-06-29	2011-08-10	Xenon Pharmaceuticals Inc	Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US20110086899A1 (en) *	2009-10-14	2011-04-14	Xenon Pharmaceuticals Inc.	Pharmaceutical compositions for oral administration
NZ599334A (en)	2009-10-14	2014-03-28	Xenon Pharmaceuticals Inc	Synthetic methods for spiro-oxindole compounds
RU2596488C2 (ru)	2010-02-26	2016-09-10	Ксенон Фармасьютикалз Инк.	Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
EP2407469A1 (en) *	2010-07-13	2012-01-18	Chemo Ibérica, S.A.	Salt of sitagliptin
CN102584860B (zh) *	2011-01-17	2014-12-10	苏州大学	含吲哚结构的螺杂环化合物及其制备方法
SG10201405403QA (en) *	2011-03-03	2014-11-27	Cadila Healthcare Ltd	Novel salts of dpp-iv inhibitor
NO3175985T3 (pt)	2011-07-01	2018-04-28
EA201491854A1 (ru)	2012-04-12	2015-03-31	Ксенон Фармасьютикалз Инк.	Асимметрический синтез соединений спирооксиндола, полезных в качестве терапевтических средств
RU2646754C2 (ru) *	2012-04-25	2018-03-07	Раквалиа Фарма Инк.	Производные пирролопиридинона в качестве ttx-s блокаторов
GB201209015D0 (en) *	2012-05-22	2012-07-04	Convergence Pharmaceuticals	Novel compounds
US9682033B2 (en)	2015-02-05	2017-06-20	Teva Pharmaceuticals International Gmbh	Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2017218920A1 (en)	2016-06-16	2017-12-21	Teva Pharmaceuticals International Gmbh	Asymmetric synthesis of funapide
EP3694510A4 (en)	2017-10-10	2021-06-30	Biogen Inc.	SPIRO DERIVATIVE PREPARATION PROCESS

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3189617A (en) *	1961-02-03	1965-06-15	Sterling Drug Inc	1-aryloxindoles and their preparation
US3723459A (en) *	1971-04-23	1973-03-27	Mc Neil Labor Inc	2-oxospiro (indoline -3,4{40 -thiochroman) derivatives
US3845770A (en) *	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
SE400966B (sv) *	1975-08-13	1978-04-17	Robins Co Inc A H	Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4670566A (en) *	1979-07-12	1987-06-02	A. H. Robins Company, Incorporated	3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4326525A (en) *	1980-10-14	1982-04-27	Alza Corporation	Osmotic device that improves delivery properties of agent in situ
US4440785A (en) *	1980-10-30	1984-04-03	A. H. Robins Company, Inc.	Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation
US4438130A (en) *	1981-11-12	1984-03-20	The Upjohn Company	Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
JPS60142984A (ja) *	1983-12-28	1985-07-29	Kyorin Pharmaceut Co Ltd	新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法
US5182289A (en) *	1988-06-14	1993-01-26	Schering Corporation	Heterobicyclic compounds having antiinflammatory activity
US5023265A (en) *	1990-06-01	1991-06-11	Schering Corporation	Substituted 1-H-pyrrolopyridine-3-carboxamides
US5116854A (en) *	1991-06-28	1992-05-26	Pfizer Inc.	Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles
US5686624A (en) *	1992-01-30	1997-11-11	Sanofi	1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) *	1992-01-30	1997-09-02	Sanofi	1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) *	1992-01-30	1998-12-15	Sanofi	1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5278162A (en) *	1992-09-18	1994-01-11	The Du Pont Merck Pharmaceutical Company	3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man
US5296478A (en) *	1992-10-07	1994-03-22	The Dupont Merck Pharmaceutical Co.	1-substituted oxindoles as cognition enhancers
US5776936A (en) *	1992-11-13	1998-07-07	Pharmacia & Upjohn Company	Marcfortine/paraherquamide derivatives useful as antiparasitic agents
DE4242451A1 (de) *	1992-12-16	1994-06-23	Basf Ag	Verfahren zur Herstellung von 5-Ringheterocyclen
FR2708606B1 (fr) *	1993-07-30	1995-10-27	Sanofi Sa	Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
AT400950B (de) *	1994-02-04	1996-04-25	Immodal Pharmaka Gmbh	Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen
EP0754183A1 (fr) *	1994-04-07	1997-01-22	Cemaf	Nouveaux derives de spiro[indole-pyrrolidine] agonistes melatoninergiques, leur procede de preparation et leur utilisation a titre de medicament
US5618819A (en) *	1994-07-07	1997-04-08	Adir Et Compagnie	1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds
FR2740136B1 (fr) *	1995-10-24	1998-01-09	Sanofi Sa	Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2757157B1 (fr) *	1996-12-13	1999-12-31	Sanofi Sa	Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
WO1998031378A1 (de) *	1997-01-20	1998-07-23	Immodal Pharmaka Gesellschaft Mbh	Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
US20040038970A1 (en) *	1998-06-12	2004-02-26	Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp.	Beta-carboline compounds
US6407101B1 (en) *	1999-05-04	2002-06-18	American Home Products Corporation	Cyanopyrroles
US6355648B1 (en) *	1999-05-04	2002-03-12	American Home Products Corporation	Thio-oxindole derivatives
EP1399155B1 (en) *	1999-07-21	2008-05-28	Boehringer Ingelheim Pharmaceuticals Inc.	Small molecules useful in the treatment of inflammatory disease
US6566372B1 (en) *	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
WO2003016276A2 (en) *	2001-08-14	2003-02-27	Eli Lilly And Company	3-substituted oxindole beta-3 agonists
AU2002347982A1 (en) *	2001-11-20	2003-06-10	Eli Lilly And Company	3-SUBSTITUTED OXINDOLE Beta3 AGONISTS
SE0104341D0 (sv) *	2001-12-20	2001-12-20	Astrazeneca Ab	New use
US6995144B2 (en) *	2002-03-14	2006-02-07	Eisai Co., Ltd.	Nitrogen containing heterocyclic compounds and medicines containing the same
CA2525866A1 (en) *	2003-05-16	2004-11-25	Pfizer Products Inc.	Treatment of psychotic and depressive disorders
MXPA05012392A (es) *	2003-05-16	2006-02-02	Pfizer Prod Inc	Tratamientos de ansiedad con ziprasidona.
AU2004237961A1 (en) *	2003-05-16	2004-11-25	Pfizer Products Inc.	Treatment of bipolar disorders and associated symptoms
CA2525323A1 (en) *	2003-05-16	2004-11-25	Pfizer Products Inc.	Method for enhancing cognition using ziprasidone
DE10337184A1 (de) *	2003-08-13	2005-03-10	Gruenenthal Gmbh	Substituierte 3-Pyrrolidin-Indol-Derivate
WO2005016913A1 (en) *	2003-08-19	2005-02-24	Pfizer Japan, Inc.	Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
CA2562399A1 (en) *	2004-04-08	2005-10-20	Topotarget A/S	Diphenyl - indol-2-on compounds and their use in the treatment of cancer
WO2005111024A1 (en) *	2004-05-14	2005-11-24	Pfizer Products Inc.	Pyrimidine derivatives for the treatment of abnormal cell growth
AR053710A1 (es) *	2005-04-11	2007-05-16	Xenon Pharmaceuticals Inc	Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY144968A (en) *	2005-04-11	2011-11-30	Xenon Pharmaceuticals Inc	Spiro-oxindole compounds and their uses as therapeutic agents
AR056317A1 (es) *	2005-04-20	2007-10-03	Xenon Pharmaceuticals Inc	Compuestos de oxindol y composicion farmaceutica
AR053713A1 (es) *	2005-04-20	2007-05-16	Xenon Pharmaceuticals Inc	Compuestos heterociclicos y sus usos como agentes terapeuticos
EP1877377A2 (en) *	2005-04-29	2008-01-16	Wyeth	Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles
EP1888581A2 (en) *	2005-05-16	2008-02-20	Gilead Sciences, Inc.	Hiv-integrase inhibitor compounds
CA2741024A1 (en) *	2008-10-17	2010-04-22	Xenon Pharmaceuticals Inc.	Spiro-oxindole compounds and their use as therapeutic agents

2007
- 2007-10-12 JP JP2009532603A patent/JP2010522690A/ja not_active Withdrawn
- 2007-10-12 EP EP07844222A patent/EP2076518A1/en not_active Withdrawn
- 2007-10-12 BR BRPI0719166-9A2A patent/BRPI0719166A2/pt not_active IP Right Cessation
- 2007-10-12 AU AU2007307635A patent/AU2007307635A1/en not_active Abandoned
- 2007-10-12 WO PCT/US2007/081240 patent/WO2008046046A1/en not_active Ceased
- 2007-10-12 US US12/445,271 patent/US20110237567A9/en not_active Abandoned
- 2007-10-12 CA CA002666136A patent/CA2666136A1/en not_active Abandoned
- 2007-10-12 MX MX2009003874A patent/MX2009003874A/es not_active Application Discontinuation
- 2007-10-12 CN CNA2007800376427A patent/CN101522685A/zh active Pending

Also Published As

Publication number	Publication date
CN101522685A (zh)	2009-09-02
US20100160291A1 (en)	2010-06-24
AU2007307635A1 (en)	2008-04-17
EP2076518A1 (en)	2009-07-08
US20110237567A9 (en)	2011-09-29
CA2666136A1 (en)	2008-04-17
JP2010522690A (ja)	2010-07-08
MX2009003874A (es)	2009-04-22
WO2008046046A1 (en)	2008-04-17

Publication	Publication Date	Title
BRPI0719166A2 (pt)	2014-06-03	Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos
BRPI0908225A2 (pt)	2016-11-01	derivados de piridazina e seu uso como agentes terapêuticos
BRPI0920448A2 (pt)	2018-10-23	compostos spiro-oxindol e seu uso como agentes terapêuticos
BRPI0810858A2 (pt)	2014-10-29	Derivados de 2-heteroaril-pirrolo[3,4-c] pirrol e seus usos como inibidores de scd
BRPI0909185A2 (pt)	2015-08-25	Derivado de vitamina e e seus usos
BRPI0817881A2 (pt)	2015-03-31	Compostos orgânicos e seus usos
BRPI0814267A2 (pt)	2015-03-31	Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI0810679A2 (pt)	2014-10-07	Derivados de 4-aza indol e seu uso como fungicidas
BRPI0710878A2 (pt)	2015-03-31	Compostos orgânicos e seus usos
BR112012000370A2 (pt)	2016-11-22	derivados de 1,2,4-tiazolidin-3-ona e seus usos no tratamento de câncer
BRPI0719210A2 (pt)	2015-05-05	Uso de compostos espiro-oxindol como agentes terapêuticos
BRPI0809103A2 (pt)	2016-08-02	composições de magnésio e seus usos
PT3001903T (pt)	2017-12-18	1h-pirazolo[3,4-b]piridinas e usos terapêuticos destas
BRPI1008045A2 (pt)	2016-03-15	derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia
BRPI0910746A2 (pt)	2016-07-26	reticuladores e seus usos
BRPI0718182A2 (pt)	2014-02-25	Oligorribonucleotídeos e seus usos.
BR112012000660A2 (pt)	2016-11-16	compostos heterociclos e seus usos
BRPI0913640A2 (pt)	2016-08-16	substâncias policrômicas e seus usos
BRPI1016150A2 (pt)	2016-04-19	compostos heterocíclicos e seus usos.
BRPI0813244A2 (pt)	2014-12-23	Compostos e seus usos 708
PT2473527T (pt)	2017-02-27	Formulações estáveis de polipéptidos e seus usos
IL205251A0 (en)	2010-12-30	Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
BRPI1012697A2 (pt)	2016-03-29	derivados imidazo[1,2-a]piridina substituídos, composições farmacêuticas, e métodos de uso como inibidores da b-secretase
BRPI0913885A2 (pt)	2015-08-25	Tiadiazoliloxifenilamidinas e seus uso como fungicidas
BRPI0817234A2 (pt)	2014-09-30	Análogos de azacitidina e seus usos

Legal Events

Date	Code	Title	Description
2014-08-26	B08L	Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]	Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 4A, 5A, 6A E 7A ANUIDADES.
2020-11-10	B08I	Publication cancelled [chapter 8.9 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.
2020-11-17	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 4A, 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.
2021-03-09	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.